Becker Muscular Dystrophy (BMD) is a related dystrophinopathy caused by mutations in the same gene as DMD. It typically presents later in life with a slower disease progression and affects an ...

Title: Effects of EDG-5506, a fast myosin modulator, on function and biomarkers of muscle damage in adults with Becker muscular dystrophy (P.255) Date: Friday, October 6, 2023, 2:00 – 3:00 pm ET ...

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference – Company to host an Industry Forum to discuss ...

Dr. Wong will empower and support families impacted by Duchenne and Becker muscular dystrophy, while serving as a key advisor and collaborator across the medical and research landscape.

News provided by Parent Project Muscular Dystrophy (PPMD) Mar 14, 2022, 11:15 AM ET Grant Will Help Establish Cardiac Clinic for Carriers of Duchenne and Becker Muscular Dystrophy With Goal of ...

"Early Cardiac Screening Necessary For Muscular Dystrophy Patients." ScienceDaily. ScienceDaily, 29 October 2005. <www.sciencedaily.com / releases / 2005 / 10 / 051029094357.htm>.

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseasesCapricor remains on track for the ...

Title: Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD) (349P) ...

Edgewise is sponsoring an Industry Forum, “Spotlight on Becker muscular dystrophy: Understanding the lived experience of Becker and clinical advancements with a novel agent.” ...